Conversations in IFN-y explores the latest advancements in understanding and managing secondary hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), with updates from ASH 2024. Featuring discussions by leading experts, the educational activity covers breakthroughs in diagnostic technologies. Topics covered include AI-based histology models and PET/CT imaging, therapeutic innovations such as emapalumab and reduced-intensity conditioning for HSCT. The implications of these findings for improving outcomes in diverse patient populations, including malignancy- and pregnancy-associated HLH will also be discussed.

Launch Date: January 9, 2025
Release Date: January 9, 2025
Expiration Date: December 31, 2025

FACULTY
Pui Lee, MD
Assistant Professor of Pediatrics
Boston Childrens Hospital

Ashish Kumar, MD, PhD
Professor of Pediatrics
Cincinnati Children's Hospital Medical Center

Alexei Grom, MD
Professor of Pediatrics
Research Director
Division of Rheumatology
Cincinnati Children’s Hospital Medical Center

This podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

What’s New Doc?: CAR T-cells in Multiple Myeloma, highlights key studies and publications from 2024 on the use of these agents in earlier lines of treatment. Dr. Mikhael details how approved and emerging CAR T cell agents in multiple myeloma will impact the treatment landscape and how to better integrate these agents to enable improved outcomes among patients.

Launch Date: December 19, 2024
Release Date: December 19, 2024
Expiration Date: November 30, 2025

FACULTY
Joseph Mikhael, MD, MEd, FRCPC, FACP
Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center
Chief Medical Officer, International Myeloma Foundation
Consultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research Institute
Adjunct Professor, College of Health Solutions, Arizona State University

This podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

In this Conversations in IFN-y podcast episode, emerging data from the 2024 ACR meeting is discussed, highlighting advancements in understanding genetic drivers, cytokine dynamics, and biomarkers like IL-18 and CXCL9 for improved diagnosis and monitoring. Expert insights explore new findings on liver and lung pathology in MAS, as well as updates on therapeutic innovations, including JAK inhibitors and emapalumab, and their roles in enhancing patient outcomes. Practical strategies are provided for integrating the latest research and cutting-edge diagnostics into clinical practice.

Launch Date: December 19, 2024
Release Date: December 19, 2024
Expiration Date: November 30, 2025

FACULTY
Pui Lee, MD
Assistant Professor of Pediatrics
Boston Children's Hospital

Alexei Grom, MD
Professor of Pediatrics
Research Director
Division of Rheumatology
Cincinnati Children’s Hospital Medical Center

This podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

In Highlights and Hindsight in CLL, Dr. Matthew Davids will describe the most significant ongoing studies and publications in CLL from 2024 and will detail their impact on the treatment continuum. This activity will enable participants to stay updated on the most relevant breakthroughs and improve outcomes among patients.

Launch Date: December 18, 2024
Release Date: December 18, 2024
Expiration Date: November 30, 2025

FACULTY
Matthew Davids, MD, MMSc
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institue

This podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

This podcast Clinical Clip features a leading expert highlighting the latest advances in Acute Myeloid Leukemia(AML) treatments presented at the 66th ASH Annual Meeting and Exposition from December 7-10, 2024, in San Diego, CA.

Launch Date: December 16, 2024
Release Date: December 16, 2024
Expiration Date: November 30, 2025

FACULTY
Naval Daver, MD
Director, Leukemia Research Alliance Program,
Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center

This podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link prior to listening to this podcast.

Clinical Clips in Hemophilia: Cutting-Edge Advances Presented at ASH 2024, will focus on the most exciting abstracts in hemophilia A and B that would be impactful for improved patient care. Dr. Guy Young will discuss the utility of key new evidence on replacement and non-replacement therapy to overcome current limitations and enable improved outcomes among patients.

Launch Date: December 12, 2024
Release Date: December 12, 2024
Expiration Date: November 30, 2025

FACULTY
Guy Young, MD
Professor of Pediatrics
University of Southern California Keck School of Medicine
Director, Hemostasis and Thrombosis Center
Children’s Hospital Los Angeles

This podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

https://www.practicepointcme.com/CMEHome/clinical-clips-in-hemophilia-cutting-edge-advances-presented-at-ash-2024-1

Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.

Launch Date: December 5, 2024
Release Date: December 5, 2024
Expiration Date: November 30, 2025

FACULTY
Aditya Bardia, MD, MPH, FASCO
Associate Professor, Medicine, Harvard Medical School
Attending Physician, Medical Oncology, Massachusetts General Hospital
Dana-Farber/Harvard Cancer Center, Boston, MA

Rita Nanda, MD
Associate Professor of Medicine
Director, Breast Oncology Program
The University of Chicago Medicine Chicago, IL

This podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19

Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.

Launch Date: December 5, 2024
Release Date: December 5, 2024
Expiration Date: November 30, 2025

FACULTY
Aditya Bardia, MD, MPH, FASCO
Associate Professor, Medicine, Harvard Medical School
Attending Physician, Medical Oncology, Massachusetts General Hospital
Dana-Farber/Harvard Cancer Center, Boston, MA

Rita Nanda, MD
Associate Professor of Medicine
Director, Breast Oncology Program
The University of Chicago Medicine Chicago, IL

This podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19

Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers. It affects younger women, women of African descent, and those with BRCA1 mutations. TNBC is highly complex, with distinct subtypes that may respond differently to treatments. Recent advancements include immunotherapies, androgen receptor inhibitors, platinum-based drugs, antibody-drug conjugates, PARP inhibitors, and combination therapies. These podcast episodes address educational gaps in TNBC management, offering interactive cases, discussions on emerging treatments, and strategies to improve patient outcomes.

Launch Date: December 5, 2024
Release Date: December 5, 2024
Expiration Date: November 30, 2025

FACULTY
Aditya Bardia, MD, MPH, FASCO
Associate Professor, Medicine, Harvard Medical School
Attending Physician, Medical Oncology, Massachusetts General Hospital
Dana-Farber/Harvard Cancer Center, Boston, MA

Rita Nanda, MD
Associate Professor of Medicine
Director, Breast Oncology Program
The University of Chicago Medicine Chicago, IL

This podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

https://www.practicepointcme.com/CMEHome/talking-tnbc-advancing-treatment-in-triple-negative-breast-cancer-latest-insights-and-clinical-strategies-19

This third podcast episode in the series explores advanced understanding of primary hemophagocytic lymphohistiocytosis (HLH), focusing on its genetic basis, diagnostic innovations, and treatment strategies. The discussion highlights the pathophysiology of HLH as an interferon gamma (IFN-γ) driven disease, emphasizing the role of novel diagnostic tools such as flow cytometry and genetic panels. The panel also examines emerging therapies, including JAK inhibitors and IFN-γ monoclonal antibody (emapalumab), in improving outcomes for both primary and secondary HLH. Practical insights into balancing immunosuppression with efficacy offer guidance for optimizing patient care.

Launch Date: December 2, 2024
Release Date: December 2, 2024
Expiration Date: November 30, 2025

FACULTY
Scott Canna, MD
Assistant Professor of Pediatrics
Childrens Hospital of Philadelphia

Pui Lee, MD
Assistant Professor of Pediatrics
Boston Childrens Hospital

Ashish Kumar, MD, PhD
Professor of Pediatrics
Cincinnati Children’s Hospital Medical Center

This podcast provides accredited continuing education credits.  To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.

https://www.practicepointcme.com/CMEHome/conversations-in-ifn-y-driven-diseases-decoding-the-gamma-signal-1